Clearpoint Neuro Inc. · NASDAQ:CLPT
Clearpoint Neuro — Investor Presentation (August 2022)
19 slides from Clearpoint Neuro's investor presentation, Aug 9, 2022
Slide 1: ClearPoint Neuro - When your path is unclear, we point the way
CLEARPOINT NEURO WHEN YOUR PATH IS t WE POINT THE WAY. Nasdaq: CLPT August 2022
Slide 2: Forward-looking statements
© 2 0 2 2 C L E A R P O I N T N E U R O 2 Statements herein concerning the Company’s plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well a
Slide 3: Neuro navigation and device company and biologics delivery enabler
© 2 0 2 2 C L E A R P O I N T N E U R O 3 A Neuro Navigation and Device Company with; • A growing portfolio of Navigation, Therapy and Access Devices supporting DBS, Laser Ablation, Biopsy and Brain Computer Interface implantation • An expanding global installed base of more than 60 centers A Biolog
Slide 4: Company key facts and razor/razorblade model
4 90+ $21-22m $45.1m (A) Solana Beach, CA Key Products: Marked Platforms Capital Equipment Razor / Razorblade model with ~95% of revenue from single- use disposables and services 67% (A,C) ~5% ~95% Disposables and Services © 2 0 2 2 C L E A R P O I N T N E U R O Irvine, CA London, UK 75+ (B)
Slide 5: Primary challenge: imaging for minimally invasive procedures
© 2 0 2 2 C L E A R P O I N T N E U R O 5 PRIMARY CHALLENGE For minimally invasive procedures to be successful, the surgeon needs imaging to see into the head MRI is the best imaging tool for the brain Large, metallic frames are not MRI compatible Video source: https://www.youtube.com/watch?v=PsL9B7
Slide 6: Leverage live MR imaging to decide, guide, treat and confirm
© 2 0 2 2 C L E A R P O I N T N E U R O 6 Leverage live MR Imaging to Decide, Guide, Treat and Confirm with sub-millimetric accuracy.
Slide 7: SmartFrame XG, Array and next-generation robotic system
© 2 0 2 2 C L E A R P O I N T N E U R O 7 SmartFrame XG Trajectory Tower with ClearPoint 2.0 Software SmartFrame Array Tower with “virtual array” Software and next generation robotic system with increased automation and enabling software* ClearPoint plans to translate more than 10 years of experienc
Slide 8: ClearPoint Maestro Brain Model
© 2 0 2 2 C L E A R P O I N T N E U R O 8 1. Shape Constrained, triangular mesh model enables point- based correspondence across multiple subjects. 2. Fast and capable of peri-procedural imaging without CPU acceleration. 3. This model is the basis for future navigation tools, for both the MRI suite
Slide 9: Installed base of leading centers
-UC San Francisco j . Stanford University — i'd Children’s Hospital Benioff Children’s Hospital Sah Francisco VA. “USC Keck Hospital UGSan Diego Banner Neh Tutson) Ohio State University Methodist Hospital San A Barnes-Jewish Hospital * Froedtert Hospital CLEARPOINT University of Wisconsi University
Slide 10: Platform runs on all major scanners; partners
10 PLACE LASER ABLATION PROBES VISUALASE CLPT PLATFORM RUNS ON ALL MAJOR SCANNERS © 2 0 2 2 C L E A R P O I N T N E U R O IMPLANT NEURO STIMULATION LEADS … More than 45 active pharma/biotech, academic, and contract research organization partners DELIVER BIOLOGICS AND DRUGS *In partnership with Clini
Slide 11: Revenue and case growth
$2.6 $3.4 $4.0 $5.2 $5.4 $7.1 $6.3 $8.1 $0.9 $1.1 $1.0 $1.4 $0.8 $1.7 $1.5 $1.4 $0.6 $1.2 $0.8 $0.6 $1.1 $2.4 $5.0 $6.8 2014 2015 2016 2017 2018 2019 2020 2021 2022 Biologics and Drug Delivery Capital and Software Functional Neurosurgery 163 267 380 503 629 670 801 682* 929 2013 2014 2015 2016 2017
Slide 12: Target indications and addressable market
Parkinson’s Disease 1,000,0001 60,0001 • $270 M - $1.35 B Drug Resistant Epilepsy 1,000,0002 11,0003 • $49.5 M - $198 M Refractory Essential Tremor 3,500,0004 60,0005 $180 M - $1.08 B Brain Tumors (n=3)6 35,0007,8 13,3007,8 $33.3 M - $300 M Severe Obsessive-Compulsive Disorder 500,0009,10 10,0009,10
Slide 13: References
© 2 0 2 2 C L E A R P O I N T N E U R O 13 1. “Parkinson’s Disease Statistics,” Parkinson’s News Today, https://parkinsonsnewstoday.com/parkinsons-disease-statistics/#:~:text=An%20estimated%20seven%20to%2010,who%20are%2080%20and%20older 2. Neurona Therapeutics. (2021 November 4). Neurona Therapeutic
Slide 14: Product development pipeline and expected first use
© 2 0 2 2 C L E A R P O I N T N E U R O 14 Expected 2022 First-Use* Expected First-Clinical Use by 2025* Fu n ct io n al N av ig at io n & T h e ra p y B io lo gi cs & D ru g D e liv e ry , A cc e ss T e ch n o lo gi e s ClearPoint Neuro Navigation Software v. 2.1 ClearPoint Maestro™ Brain Model Orc
Slide 15: Worldwide training and remote support facility
© 2 0 2 2 C L E A R P O I N T N E U R O 15 • Simulated training experience for surgeons and staff to perform mock procedures and provide development pipeline feedback • Showcase new technologies to Pharmaceutical and BCI partners • Home for Clinical Specialists to support cases remotely without trav
Slide 16: 4 pillar growth strategy by 2025
NEW THERAPY DEVICES NEURO NAVIGATION FOR DBS & BCI BIOLOGICS & DRUG DELIVERY 20252022 4 Pillar Growth Strategy by 2025 Target Indications of > 1,000,000 Patients Diagnosed Each Year Potential Total Addressable Market for CLPT of $12B+ Enter the Neuro Laser Ablation Market Launch Maestro Brain Model
Slide 17: Investment summary
© 2 0 2 2 C L E A R P O I N T N E U R O 17 Unique platform technology enabling Precision MRI-Guided Therapies to restore quality of life for some of the most debilitating disorders Large, growing installed base in 60+ of 500+ leading Neurosurgery and research centers Worldwide Expandable Platform wi
Slide 18: Nasdaq listing
) N q as Nasda 00 daq C a Nasdaqi “ “1.57% — comp + 0.20% 7a NASOAQIOO ag 962358 3180 sne.20 921 97118 on nergy: sthealay Eid imateho'ou @ cisco. COMCAST Sapsico
Slide 19: ClearPoint Neuro
CLEARPOINT NEURO
ClearPoint Neuro — Investor Presentation (August 2022) on 6ix